Compare LVS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVS | RVMD |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 30.1B |
| IPO Year | 2004 | N/A |
| Metric | LVS | RVMD |
|---|---|---|
| Price | $45.99 | $195.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $69.21 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 5.1M | 1.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 19.90 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $13,017,000,000.00 | N/A |
| Revenue This Year | $7.24 | N/A |
| Revenue Next Year | $4.49 | $533.02 |
| P/E Ratio | $33.35 | ★ N/A |
| Revenue Growth | ★ 15.22 | N/A |
| 52 Week Low | $44.21 | $34.00 |
| 52 Week High | $70.45 | $194.56 |
| Indicator | LVS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 61.42 |
| Support Level | $44.22 | $177.04 |
| Resistance Level | $54.81 | N/A |
| Average True Range (ATR) | 1.30 | 7.99 |
| MACD | 0.13 | -0.16 |
| Stochastic Oscillator | 37.05 | 88.99 |
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.